Trial Profile
Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2024
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Iodine radioactive
- Indications Thyroid cancer
- Focus Pharmacodynamics
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 17 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Aug 2012 Actual initiation date (1 Jul 2012) added as reported by ClinicalTrials.gov.